Stock data
| Market cap. | €317m |
| Last close | €10.00 |
| High / Low (52 weeks) | €13.2 / €7.0 |
| Stock market listing | Euronext Paris |
| Forecast net cash (€m) | 114 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 9.4092 | 36.7989 | (32.4324) |
| Relative * | 5.2228 | 13.652 | (22.2288) |
* % Relative to local index
Other companies covered in sector
| Y/E Dec | Revenue (€m) | EBITDA (€m) | PBT (€m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2009A | 11.8 | (25.1) | (27.0) | (122.0) | N/A | N/A |
| 2010A | 14.1 | (32.2) | (33.8) | (122.5) | N/A | N/A |
| 2011E | 14.6 | (36.4) | (37.7) | (119.1) | N/A | N/A |
| 2012E | 13.3 | (42.3) | (44.3) | (139.8) | N/A | N/A |
Last updated on 17/01/2012
Latest research
Coming of age
Outlook | Pharmaceutical & Healthcare | 17/01/2012
Promising times ahead
QuickView | Pharmaceutical & Healthcare | 31/05/2011
Focused strategy
QuickView | Pharmaceutical & Healthcare | 17/03/2011
Investment summary
Transgene is an immunotherapy drug development company that could become a fully-integrated pharmaceutical company over the next five years. After many years of development, TG4010 is about to start a Phase IIb/III trial, which could lead to Novartis exercising its option to in-license the product. Its oncolytic virus, JX594 (TG6006), has entered Phase IIb and data from two other Phase II trials could lead to Transgene partnering them. We value Transgene at €620m.
Last updated on 17/01/2012
Key management
| Philippe Archinard, Chairman & CEO |
| Stephane Boissel, CFO |
Company address
| Boulevard Gonthier d’Andernach Parc d’Innovation - CS80166 Illkirch-Graffensta F-67405 France View website |
